Wolverine Stack Dosing Protocol: BPC-157 + TB-500

Quick Reference Dosing Card

What Is the Wolverine Stack?

The Wolverine Stack is a two-peptide tissue repair peptide blend that combines BPC-157 and TB-500. The name comes from the rapid-regeneration idea, and the logic behind it is straightforward: one peptide works locally at the injury site, the other supports repair across your whole body.

BPC-157 focuses on the area around an injury. It helps build new blood vessels (angiogenesis), supports blood-flow signaling, and protects nearby cells from further damage. TB-500 works systemically, it helps repair cells move to where they're needed, recruits stem-like progenitor cells, and promotes organized tissue healing instead of scar tissue buildup.

Together, the two peptides are designed to cover both sides of recovery: the local repair environment and the body-wide logistics that deliver repair resources to it. No clinical trial has tested the BPC-157 + TB-500 combination directly. Current Wolverine Stack protocols are based on individual compound evidence and community usage patterns.

How the Wolverine Stack Works

The Wolverine Stack works through four complementary pathways. Think of it as a division of labor: BPC-157 handles the local construction site, and TB-500 manages the supply chain.

Pathway 1: Blood Supply + Cell Delivery

BPC-157 builds new blood vessels at the injury site — like laying roads to a construction zone. TB-500 helps repair cells physically travel through those pathways by reorganizing their internal structure (cytoskeletal regulation), getting the right cells to the right place.

Pathway 2: Local Protection + Body-Wide Repair Recruitment

BPC-157 protects the tissue around an injury from additional damage, keeping the local environment stable. TB-500 recruits stem-like progenitor cells from elsewhere in the body and directs them toward the repair site — a systemic mobilization layer.

Pathway 3: Repair Signals + Organized Healing

BPC-157 triggers growth-factor signals that tell the body "repair here." TB-500 helps ensure that new tissue forms in an organized, functional way rather than as disordered scar tissue (anti-fibrotic remodeling).

Pathway 4: Daily + Twice-Weekly Timing

Daily BPC-157 provides continuous local repair support. Twice-weekly TB-500 adds a sustained systemic repair layer across the cycle. The different dosing schedules mean both short-term and longer-term recovery signals are active throughout.

Wolverine Stack Dosing Protocol & Schedule

This section covers three ways to run the Wolverine Stack dosing protocol: separate vials (most flexible), a pre-blended vial (most convenient), and an oral hybrid option. Choose the format that fits your workflow, then follow the loading and maintenance phases below.

In the dosing tables below, SubQ means a subcutaneous injection placed just under the skin into the fat layer.

• On TB-500 days (often Monday/Thursday), both peptides can be administered in the same session using separate syringes.
• BPC-157 is usually injected near the injury site while TB-500 is injected at any convenient SubQ site.
• No strict spacing is required between injections when both are given in one session.
• Avoid mixing separate-vial peptides in one syringe due to differing stability and formulation behavior.
• Pre-blended Wolverine vials improve convenience but reduce dose flexibility versus separate vials.
• For gut-focused workflows, oral BPC-157 can be paired with injectable TB-500.

Wolverine Stack Reconstitution Guide

Reconstitution is the process of mixing your freeze-dried peptide powder with bacteriostatic (BAC) water to create an injectable solution. Because the Wolverine Stack uses two compounds, you'll either reconstitute each vial separately or use a single pre-blended vial. The tables below show the exact water volumes, concentrations, and syringe units for each option. A U-100 syringe is a standard insulin syringe where 100 units equals 1 mL of liquid.

• BPC-157 is dosed in micrograms; TB-500 is dosed in milligrams.
• BPC-157 reconstituted stability is typically up to 30 days refrigerated.
• TB-500 reconstituted stability is shorter, usually 1-2 weeks refrigerated.
• Use bacteriostatic water for multi-dose workflows.

Standard 7-Step Reconstitution (Both Compounds)

1. Remove cap and wipe stopper with alcohol swab.
2. Draw the selected BAC water volume into a sterile syringe.
3. Direct water against the vial wall, not directly onto powder.
4. Allow water to flow slowly down the glass.
5. Gently roll between palms for 30-60 seconds; do not shake.
6. Verify solution clarity; discard if cloudy.
7. Label peptide, date, and concentration; refrigerate at 2-8C.

Wolverine Stack Side Effects & Safety

Both compounds have favorable individual safety profiles, but no clinical trials have tested the Wolverine Stack combination directly.

The main safety discussions around the Wolverine Stack center on three areas: (1) both peptides promote new blood vessel growth, so using them together may amplify that effect — which is a concern for anyone with cancer or a recent cancer history, since tumor growth also relies on blood vessel formation; (2) contamination risk from unregulated research-grade sources; and (3) the added complexity of managing two injection schedules (daily plus twice-weekly).

Here's what community users commonly report:

• Mild injection-site irritation (redness, slight swelling)
• Temporary fatigue during the TB-500 loading phase
• Occasional mild headache
• No consistent combination-specific adverse pattern has been identified
• Neither peptide is known to require post-cycle therapy in typical research-style protocols
• Product quality is a primary practical risk when running multi-peptide protocols — always verify COAs from your supplier

Clinical Evidence Context

BPC-157 Evidence Base

BPC-157 has been widely studied in animal and lab models (preclinical research) covering tendons, ligaments, muscle, gut, and nerve/blood vessel injuries. However, formal human clinical trial data remains limited — most of what we know comes from these animal studies, not from controlled trials in people.

TB-500 Evidence Base

TB-500 has progressed further in human testing. Phase I trials (small studies focused on safety) showed it was well-tolerated, and Phase II trials (larger studies testing effectiveness) showed early positive signals in specific conditions. It also has preclinical research supporting its role in blood vessel growth, cell migration, and organized tissue repair.

Synergy Rationale (Mechanistic, Not Clinical)

The Wolverine rationale is based on how each peptide works, not on direct combination trial data. BPC-157 supports blood flow and protects tissue around the injury site, while TB-500 helps move repair resources through the body and supports more organized healing with less scar-tissue-heavy remodeling.

Storage & Handling

TB-500 has the shorter reconstituted window, so practical stack workflows usually reconstitute TB-500 more frequently than BPC-157.

Wolverine Stack vs Individual Peptides

Choose Wolverine when the objective is maximum tissue-repair coverage across local and systemic pathways. Choose single-compound protocols when simplicity, lower cost, or narrower targeting is preferred.

Related Stacking Protocols

Wolverine + GH Secretagogue

• Compounds: BPC-157 Protocol + TB-500 Protocol + CJC-1295 Protocol / Ipamorelin Protocol at bedtime.
• Rationale: add GH pulse support during deep sleep to complement tissue-repair pathways.

Wolverine + GHK-Cu

• Compounds: BPC-157 Protocol + TB-500 Protocol + GHK-Cu Protocol.
• Rationale: add collagen/ECM remodeling and skin-quality improvements to structural repair.
• See the GLOW Stack Protocol for this three-peptide model.

Frequently Asked Questions - Wolverine Stack

Sources & Research

1. Vasireddi N, et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." Orthopaedic Journal of Sports Medicine, 2025 Link.
2. Ruff D, et al. "A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers." Annals of the New York Academy of Sciences, 2010 Link.
3. Bock-Marquette I, et al. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature, 2004.
4. Smart N, et al. "Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization." Nature, 2007.
5. Guarnera G, et al. "The effect of thymosin treatment of venous ulcers." Annals of the New York Academy of Sciences, 2010.
6. Philp D, et al. "Thymosin beta4 promotes angiogenesis, wound healing, and hair growth." FASEB Journal, 2004.
7. Gwyer D, et al. "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing." Cell and Tissue Research, 2019 Link.
8. Ehrlich HP, Hazard SW "Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts." Annals of the New York Academy of Sciences, 2010.
9. Sikiric P, et al. "The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity." Pharmaceuticals, 2024 Link.
10. Maar K, et al. "Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State." Cells, 2021 Link.
11. Sosne G, et al. "Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial." Cornea, 2015.
12. Alpha Bio Med "Wolverine Blend Dosing Guide (BPC-157 + TB-500)." Provider Dosing Guide PDF, n.d. Link.
13. BioMed Peptides "Wolverine Blend | BPC157 + TB500 (Clinical Dosing Guide)." Provider Product and Dosing Reference, n.d. Link.
14. Multifunctionality Review "Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review." Pharmaceuticals, 2025 Link.

Related Protocols

Disclaimer